Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin Dreesen

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
British Journal of Clinical Pharmacology|March 24, 2026
Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and childrenZoë Vander Elst, Pieter-Jan Spiessens, Dorian Vanneste, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 16, 2022
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseasesWannee Kantasiripitak, An Outtier, Sebastian G Wicha, et al.
Journal of Crohn'S & Colitis|January 8, 2016
Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative ColitisIris Detrez, Erwin Dreesen, Thomas Van Stappen, et al.
Clinics and Research in Hepatology and Gastroenterology|May 16, 2024
Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel diseaseSeverine Vermeire, Marla C Dubinsky, Shervin Rabizadeh, et al.
Inflammatory Bowel Diseases|November 17, 2021
Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD StudyJurij Hanzel, Erwin Dreesen, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|June 17, 2021
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD StudyJurij Hanzel, Erwin Dreesen, Séverine Vermeire, et al.
Cellular Oncology (Dordrecht, Netherlands)|June 18, 2024
The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanismMichiel Remmerie, Rüveyda Dok, Zhigang Wang, et al.
Journal of Thrombosis and Haemostasis : JTH|July 5, 2025
Population pharmacokinetics of edoxaban in geriatric patients with atrial fibrillationAngela Elma Edwina, Lorenz Van der Linden, Louise Debruyne, et al.
Journal of Crohn'S & Colitis|September 11, 2019
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD PatientsBram Verstockt, Evelien Mertens, Erwin Dreesen, et al.
Medical Mycology|September 20, 2022
Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic studyRuth Van Daele, Joost Wauters, Omar Elkayal, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
British Journal of Clinical Pharmacology|March 24, 2026
Systematic review and scoring-based selection of pharmacokinetic models for precision dosing of vancomycin in neonates and childrenZoë Vander Elst, Pieter-Jan Spiessens, Dorian Vanneste, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 16, 2022
Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseasesWannee Kantasiripitak, An Outtier, Sebastian G Wicha, et al.
Journal of Crohn'S & Colitis|January 8, 2016
Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative ColitisIris Detrez, Erwin Dreesen, Thomas Van Stappen, et al.
Clinics and Research in Hepatology and Gastroenterology|May 16, 2024
Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel diseaseSeverine Vermeire, Marla C Dubinsky, Shervin Rabizadeh, et al.
Inflammatory Bowel Diseases|November 17, 2021
Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD StudyJurij Hanzel, Erwin Dreesen, Séverine Vermeire, et al.
Inflammatory Bowel Diseases|June 17, 2021
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD StudyJurij Hanzel, Erwin Dreesen, Séverine Vermeire, et al.
Cellular Oncology (Dordrecht, Netherlands)|June 18, 2024
The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanismMichiel Remmerie, Rüveyda Dok, Zhigang Wang, et al.
Journal of Thrombosis and Haemostasis : JTH|July 5, 2025
Population pharmacokinetics of edoxaban in geriatric patients with atrial fibrillationAngela Elma Edwina, Lorenz Van der Linden, Louise Debruyne, et al.
Journal of Crohn'S & Colitis|September 11, 2019
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD PatientsBram Verstockt, Evelien Mertens, Erwin Dreesen, et al.
Medical Mycology|September 20, 2022
Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic studyRuth Van Daele, Joost Wauters, Omar Elkayal, et al.
Pageof 11